시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 고콜레스테롤혈증 시장 보고서(2025년)
Hypercholesterolemia Global Market Report 2025
상품코드 : 1720816
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,487,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,376,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,266,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

고콜레스테롤혈증 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 콜레스테롤 관련 리스크에 대한 의식의 고조 등의 요인에 의한 것으로 예측됩니다. 지방 동향으로는 지질 프로파일링의 진보, 로봇 지원 수술의 이용, 드러그 딜리버리에 있어서의 나노 테크놀로지의 응용, 원격 의료 플랫폼의 대두, 리포단백 표적에 대한 주목 등을 들 수 있습니다.

심혈관 질환의 유병률 증가는 향후 수년간 고콜레스테롤혈증 시장의 성장을 가속할 것으로 예측됩니다. 심혈관 질환의 증가는 주로 건강에 해로운 식단, 신체 활동 부족, 비만율 증가, 만성 스트레스, 인구 고령화, 고혈압 및 당뇨병과 같은 질환의 유병률에 기인합니다. 심장 마비, 뇌졸중 및 기타 심혈관 합병증의 위험을 줄임으로써 심혈관 질환 환자를 지원합니다. 2024년 10월에 미국 질병통제예방센터는 매년 약 805,000명이 심장마비를 경험하고 있으며 그 중 60만 5,000명이 처음 발생하는 사건이고, 20만명이 심장 마비 기왕력이 있는 사람입니다. 그 때문에 심혈관 질환의 이환율 증가는 고콜레스테롤혈증 시장을 촉진할 것으로 예측됩니다.

고콜레스테롤혈증 시장의 주요 진출기업은 치료 효과를 높이고 환자의 컴플라이언스를 향상시키기 위해 3제 병용약 등의 혁신적인 제품을 개발하고 있습니다. 삼중 결합 약물은 정제나 캡슐과 같은 세 가지 활성 성분을 단일 용량 형태로 결합한 것입니다. 예를 들면, 2025년 2월, 한국의 제약회사 셀트리온사가 고혈압 및 고지혈증 치료제인 암로제트 정제를 출시했습니다. 이 약물은 고혈압의 칼슘 채널 차단제인 암로디핀, 콜레스테롤을 낮추는 스타틴인 로수바스타틴, 장내 콜레스테롤 흡수를 줄이는 데 도움이 되는 에제티미브 등 세 가지 활성 성분을 결합한 것입니다. 이 약물은 네 가지 용량 조합(5/5/10 mg, 5/10/10 mg, 10/5/10 mg, 10/10 mg)으로 제공되며, 암로디핀 투여 시 고혈압 및 심근 허혈, 로수바스타틴-에제티미브 병용 시 일차성 고콜레스테롤혈증, 만성 안정 협심증 또는 혈관성 협심증 완화에도 사용됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Hypercholesterolemia refers to an abnormally high level of cholesterol in the blood, particularly low-density lipoprotein (LDL) cholesterol, which increases the risk of atherosclerosis and cardiovascular diseases such as heart attacks and strokes. It is often influenced by genetic factors, poor diet, lack of physical activity, and underlying health conditions such as diabetes or hypothyroidism.

The primary types of hypercholesterolemia are genetic and acquired. Genetics refers to the study of genes, heredity, and the variation of inherited traits in living organisms, which play a crucial role in determining susceptibility to various conditions, including familial hypercholesterolemia. Treatment for hypercholesterolemia includes statins, bile acid resins, niacin, PCSK9 inhibitors, cholesterol absorption inhibitors, fibric acid derivatives, and other medications. These treatments are available in oral and injectable forms. They are distributed through various channels, such as hospital pharmacies, retail pharmacies, and other outlets, and are used by a wide range of end users, including hospitals, specialty clinics, home healthcare providers, and others.

The hypercholesterolemia market research report is one of a series of new reports from The Business Research Company that provides hypercholesterolemia market statistics, including hypercholesterolemia industry global market size, regional shares, competitors with a hypercholesterolemia market share, detailed hypercholesterolemia market segments, market trends and opportunities, and any further data you may need to thrive in the hypercholesterolemia industry. This hypercholesterolemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hypercholesterolemia market size has grown rapidly in recent years. It will grow from $16.30 billion in 2024 to $18.66 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth during the historic period can be attributed to several factors, including the rise of health campaigns, increased investment in research and development, a growing emphasis on preventive healthcare, and the expansion of preventive health screenings alongside lifestyle modifications.

The hypercholesterolemia market size is expected to see rapid growth in the next few years. It will grow to $31.70 billion in 2029 at a compound annual growth rate (CAGR) of 14.2%. The growth during the forecast period can be attributed to factors such as improved diagnosis and screening, government initiatives and health policies, the growing prevalence of risk factors, the increasing availability of over-the-counter (OTC) cholesterol-lowering products, and heightened awareness of cholesterol-related risks. Key trends include advancements in lipid profiling, the use of robotic-assisted surgeries, the application of nanotechnology in drug delivery, the rise of telemedicine platforms, and the focus on lipoprotein targeting.

The growing prevalence of cardiovascular diseases is expected to drive the growth of the hypercholesterolemia market in the coming years. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels. The rise in cardiovascular diseases is largely due to unhealthy diets, physical inactivity, increasing obesity rates, chronic stress, aging populations, and the prevalence of conditions such as hypertension and diabetes. Hypercholesterolemia treatments help cardiovascular disease patients by lowering LDL cholesterol levels, reducing plaque buildup in the arteries, improving blood flow, and decreasing the risk of heart attacks, strokes, and other cardiovascular complications. For instance, in October 2024, the Centers for Disease Control and Prevention reported that around 805,000 people in the United States experience a heart attack each year, with 605,000 being first-time incidents and 200,000 occurring in individuals with a history of previous heart attacks. Therefore, the rising incidence of cardiovascular diseases is expected to propel the hypercholesterolemia market.

Key players in the hypercholesterolemia market are developing innovative products, such as triple-combination drugs, to improve treatment efficacy and enhance patient compliance. A triple-combination drug combines three active ingredients into a single dosage form, such as a tablet or capsule. For example, in February 2025, Celltrion Pharm, Inc., a South Korea-based pharmaceutical company, launched Amrozet Tablet, a drug for hypertension and hyperlipidemia. This medication combines three active ingredients such as amlodipine, a calcium channel blocker for hypertension; rosuvastatin, a statin to lower cholesterol; and ezetimibe, which helps reduce cholesterol absorption in the intestines. The drug is available in four dosage combinations (5/5/10 mg, 5/10/10 mg, 10/5/10 mg, and 10/10/10 mg) and is indicated for hypertension and myocardial ischemia under amlodipine, primary hypercholesterolemia under the rosuvastatin-ezetimibe combination, and also for relieving chronic stable angina or vasospastic angina. Additionally, it helps reduce the risk of hospitalization for angina and heart surgery in patients with documented coronary artery disease.

In August 2023, HDL Therapeutics, Inc., a U.S.-based biotechnology company, merged with Swiftmerge Acquisition Corp. for an undisclosed amount. This merger aims to accelerate the commercialization of HDL Therapeutics' FDA-approved Plasma Delipidation System (PDS-2) for treating patients with homozygous familial hypercholesterolemia (HoFH). Swiftmerge Acquisition Corp. is a U.S.-based special purpose acquisition company (SPAC) focused on providing treatment for HoFH.

Major players in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., Melinta Therapeutics Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.

North America was the largest region in the hypercholesterolemia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hypercholesterolemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hypercholesterolemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hypercholesterolemia market consists of sales of omega-3 fatty acid supplements, atorvastatin, and simvastatin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hypercholesterolemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hypercholesterolemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for hypercholesterolemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hypercholesterolemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Hypercholesterolemia Market Characteristics

3. Hypercholesterolemia Market Trends And Strategies

4. Hypercholesterolemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Hypercholesterolemia Growth Analysis And Strategic Analysis Framework

6. Hypercholesterolemia Market Segmentation

7. Hypercholesterolemia Market Regional And Country Analysis

8. Asia-Pacific Hypercholesterolemia Market

9. China Hypercholesterolemia Market

10. India Hypercholesterolemia Market

11. Japan Hypercholesterolemia Market

12. Australia Hypercholesterolemia Market

13. Indonesia Hypercholesterolemia Market

14. South Korea Hypercholesterolemia Market

15. Western Europe Hypercholesterolemia Market

16. UK Hypercholesterolemia Market

17. Germany Hypercholesterolemia Market

18. France Hypercholesterolemia Market

19. Italy Hypercholesterolemia Market

20. Spain Hypercholesterolemia Market

21. Eastern Europe Hypercholesterolemia Market

22. Russia Hypercholesterolemia Market

23. North America Hypercholesterolemia Market

24. USA Hypercholesterolemia Market

25. Canada Hypercholesterolemia Market

26. South America Hypercholesterolemia Market

27. Brazil Hypercholesterolemia Market

28. Middle East Hypercholesterolemia Market

29. Africa Hypercholesterolemia Market

30. Hypercholesterolemia Market Competitive Landscape And Company Profiles

31. Hypercholesterolemia Market Other Major And Innovative Companies

32. Global Hypercholesterolemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hypercholesterolemia Market

34. Recent Developments In The Hypercholesterolemia Market

35. Hypercholesterolemia Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기